Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings.
Prostate cancer is the most common cancer diagnosed and the second leading cause of cancer-related deaths in men in the United States. The etiological factors that give rise to prostate cancer are not known. Therefore, it is not possible to develop primary intervention strategies to remove the causative agents from the environment. However, secondary intervention strategies with selenium (Se) compounds and other agents represent a viable option to reduce the morbidity and mortality of prostate cancer. In this review, we discuss ongoing clinical trials. In addition, we discuss preclinical mechanistic studies that provide insights into the biochemical and molecular basis for the anti-carcinogenic activity of both inorganic and organic forms of Se.
Meuillet
Emmanuelle
E
Department of Molecular and Cellular Biology, Arizona Cancer Center, The University of Arizona College of Medicine, Tucson, Arizona 85724, USA. mnelson@zacc.arizona.edu
Stratton
Suzanne
S
Prasad Cherukuri
Durga
D
Goulet
Anne-Christine
AC
Kagey
Jacob
J
Porterfield
Bruce
B
Nelson
Mark A
MA
D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004608:Eligibility Determination / Q000145:classification; D006801:Humans; D008297:Male; D008954:Models, Biological; D016566:Organoselenium Compounds / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012643:Selenium / Q000378:metabolism / Q000627:therapeutic use*; D018038:Sodium Selenite / Q000378:metabolism; D014810:Vitamin E / Q000627:therapeutic use
D016566:Organoselenium Compounds; D014810:Vitamin E; D012643:Selenium; D018038:Sodium Selenite